We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Edpidarex Exeed Aims To Advance Innovation in Drug Discovery
Product News

Edpidarex Exeed Aims To Advance Innovation in Drug Discovery

Edpidarex Exeed Aims To Advance Innovation in Drug Discovery
Product News

Edpidarex Exeed Aims To Advance Innovation in Drug Discovery


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Edpidarex Exeed Aims To Advance Innovation in Drug Discovery"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Epidarex Capital has announced the launch of its therapeutic discovery engine, Epidarex Exeed Ltd. (Exeed). Focused on advancing early stage, innovative life science assets, Exeed aims to pair world-class science with leading drug discovery, project management and CRO partners under the leadership of an experienced management team, with seed funds provided by Epidarex Capital.

Exeed has been founded to efficiently and rapidly transform breakthrough life science innovations into investable assets over a period of 12-18 months. The Exeed team, led by CEO Dr. Henning Steinhagen, with Daniel Gill and Richard Brooks in Operational and Finance roles, will provide significant hands-on support to de-risk early stage programs.

Dr Henning Steinhagen, CEO of Epidarex Exeed, said: “There is a clear need for early stage capital and capabilities that can validate and progress breakthrough life science innovation to a point where traditional VC investors are ready to fund companies and lead Series A investments. Epidarex Exeed will help to fulfil that need.” 

Advertisement